Back
 IJCM  Vol.11 No.5 , May 2020
COVID-19 Coronavirus: Is Infection along with Mycoplasma or Other Bacteria Linked to Progression to a Lethal Outcome?
Abstract: Most patients with COVID-19 disease caused by the SARS-CoV-2 virus recover from this infection, but a significant fraction progress to a fatal outcome. As with some other RNA viruses, co-infection or activation of latent bacterial infections along with pre-existing health conditions in COVID-19 disease may be important in determining a fatal disease course. Mycoplasma spp. (M. pneumonaie, M. fermentans, etc.) have been routinely found as co-infections in a wide number of clinical conditions, and in some cases this has progressed to a fatal disease. Although preliminary, Mycoplasma pneumoniae has been identified in COVID-19 disease, and the severity of some signs and symptoms in progressive COVID-19 patients could be due, in part, to Mycoplasma or other bacterial infections. Moreover, the presence of pathogenic Mycoplasma species or other pathogenic bacteria in COVID-19 disease may confer a perfect storm of cytokine and hemodynamic dysfunction, autoimmune activation, mitochondrial dysfunction and other complications that together cannot be easily corrected in patients with pre-existing health conditions. The positive responses of only some COVID-19 patients to antibiotic and anti-malaria therapy could have been the result of suppression of Mycoplasma species and other bacterial co-infections in subsets of patients. Thus it may be useful to use molecular tests to determine the presence of pathogenic Mycoplasma species and other pathogenic bacteria that are commonly found in atypical pneumonia in all hospitalized COVID-19 patients, and when positive results are obtained, these patients should treated accordingly in order to improve clinical responses and patient outcomes.
Cite this paper: Nicolson, G. and de Mattos, G. (2020) COVID-19 Coronavirus: Is Infection along with Mycoplasma or Other Bacteria Linked to Progression to a Lethal Outcome?. International Journal of Clinical Medicine, 11, 282-302. doi: 10.4236/ijcm.2020.115029.
References

[1]   Burki, T.K. (2020) Coronavirus in China. Lancet Respiratory Medicine, 8, 238.
https://doi.org/10.1016/S2213-2600(20)30056-4

[2]   Huang, C., Wang, Y., Li, X., Ren, I., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5
https://www.thelancet.com/journals/thelancet/article/PIIS0140-6736(20)30183-5/fulltext

[3]   Li, J.-Y., You, Z., Wang, Q., Zhou, Z.-J., Qiu, Y., Luo, R. and Ge, X.-Y. (2020) The Epidemic of 2019-Novel-Coronavirus (2019-nCov) Pneumonia and Insights for Emerging Infectious Diseases in the Future. Microbes and Infections, 22, 80-85.
https://www.sciencedirect.com/science/article/pii/S1286457920300307
https://doi.org/10.1016/j.micinf.2020.02.002


[4]   Chen, J. (2020) Pathogenicity and Transmissibility of 2019-nCov—A Quick Overview and Comparison with Other Re-Emerging Viruses. Microbes and Infections, 22, 69-71.
https://www.sciencedirect.com/science/article/pii/S1286457920300265
https://doi.org/10.1016/j.micinf.2020.01.004


[5]   Emami, A., Javanmardi, F., Pirbonyeh, N. and Akbari, A. (2020) Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Archives of Academic Emergency Medicine, 8, e35.
http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/600/754

[6]   Guo, Y.-R., Cao, Q.-D., Hong, Z.-S., Tan, Y.-Y., Chen, S.-D., Jin, H.-J., Tan, K.-S., Wang, D.-Y. and Yan, Y. (2020) The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak—An Update on the Status. Military Medical Research, 7, Article No. 11.
https://doi.org/10.1186/s40779-020-00240-0

[7]   Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., et al. (2020) Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. The Lancet Respiratory Medicine, 8, e26.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102538
https://doi.org/10.1016/S2213-2600(20)30079-5


[8]   Nicolson, G.L. (2008) Chronic Infections in Neurodegenerative and Neurobehavioral Diseases. Lab Medicine, 39, 291-299.
https://academic.oup.com/labmed/article/39/5/291/2504709
https://doi.org/10.1309/96M3BWYP42L11BFU

[9]   Nicolson, G.L. and Haier, J. (2009) Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 1. British Journal of Medical Practitioners, 2, 20-28.
https://www.bjmp.org/content/role-chronic-bacterial-and-viral-infections-neurodegenerative-
neurobehavioral-psychiatric-au


[10]   Nicolson, G.L. and Haier, J. (2010) Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses: Part 2. British Journal of Medical Practitioners, 3, e301.
https://www.bjmp.org/content/role-chronic-bacterial-and-viral-infections-neurodegenerative
-neurobehavioural-psychiatric-a


[11]   Lo, S.-C., Dawson, M.S., Newton, P.B., et al. (1989) Association of the Virus-Like Infectious Agent Originally Reported in Patients with AIDS with Acute Fatal Disease in Previously Healthy Non-AIDS Patients. American Journal of Tropical Medicine and Hygiene, 41, 364-376.
https://doi.org/10.4269/ajtmh.1989.41.364
https://www.ajtmh.org/content/journals/10.4269/ajtmh.1989.41.364

[12]   Izumikawa, K. (2016) Clinical Features of Severe or Fatal Mycoplasma pneumoniae Pneumonia. Frontiers in Microbiology, 7, Article No. 800.
https://www.frontiersin.org/articles/10.3389/fmicb.2016.00800/full
https://doi.org/10.3389/fmicb.2016.00800


[13]   Nicolson, G.L., Gan, R., Nicolson, N.L. and Haier, J. (2007) Evidence for Mycoplasma, Chlamydia pneunomiae and HHV-6 Co-Infections in the Blood of Patients with Autistic Spectrum Disorders. Journal of Neuroscience Research, 85, 1143-1148.
https://doi.org/10.1002/jnr.21203

[14]   Nicolson, G.L., Gan, R. and Haier, J. (2003) Multiple Co-Infections (Mycoplasma, Chlamydia, Human Herpes Virus-6) in Blood of Chronic Fatigue Syndrome Patients: Association with Signs and Symptoms. Acta Pathologica Microbiologica Immunologica Scandanavia (APMIS), 111, 557-566.
https://doi.org/10.1034/j.1600-0463.2003.1110504.x

[15]   Nicolson, G.L., Nicolson, N.L. and Haier, J. (2008) Chronic Fatigue Syndrome Patients Subsequently Diagnosed with Lyme Disease Borrelia burgdorferi: Evidence for Mycoplasma Species Co-Infections. Journal of Chronic Fatigue Syndrome, 14, 5-17.
https://doi.org/10.1080/10573320802091809

[16]   Berghoff, W. (2012) Chronic Lyme Disease and Co-Infections: Differential Diagnosis. Open Neurology Journal, 6, 158-178.
https://openneurologyjournal.com/VOLUME/6/PAGE/158/FULLTEXT
https://doi.org/10.2174/1874205X01206010158

[17]   Chiu, C.-Y., Chen, C.-J., Wong, K.-S., Tsai, M.-H., Chiu, C.-H. and Huang, Y.-C. (2015) Impact of Bacterial and Viral Coinfection on Mycoplasmal Pneumonia in Childhood Community-Acquired Pneumonia. Journal of Microbiology, Immunology and Infection, 48, 51-56.
https://doi.org/10.1016/j.jmii.2013.06.006
https://www.sciencedirect.com/science/article/pii/S1684118213001102

[18]   Hon, E.K.L., Ip, M., Chu, W.C.W. and Wong, W. (2012) Megapneumonia Coinfection: Pneumococcus, Mycoplasma pneumoniae, and Metaneumovirus. Case Reports in Medicine, 2012, Article ID: 310104.
https://doi.org/10.1155/2012/310104
https://www.hindawi.com/journals/crim/2012/310104

[19]   Kim, J.H., Kwon, J.H., Lee, J.-Y., Lee, J.S., Ryu, J.-M., Kim, S.-H., Lim, K.S. and Kim, W.Y. (2018) Clinical Features of Mycoplasma pneumoniae Coinfection and Need for Its Testing in Influenza Pneumonia Patients. Journal of Thoracic Disease, 10, 6118-6127.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297417
https://doi.org/10.21037/jtd.2018.10.33


[20]   Toikka, P., Juvén, T., Virkki, R., Leinonen, M., Mertsola, J. and Ruuskanen, O. (2000) Streptococcus pneumoniae and Mycoplasma pneumonia in Community-Acquired Pneumonia. Archives of Disease in Childhood, 83, 413-414.
https://adc.bmj.com/content/archdischild/83/5/413.full.pdf
https://doi.org/10.1136/adc.83.5.413

[21]   Berrajah, L.F., Ben Slama, K.A., Khbou, I., Gargouri, S., Chtourou, A., Znazen, A., et al. (2018) Virus et Bactéries Atypiques Détectés dan les Infections Respiratoires Basses Communautaires de L’enfant Dans le Region de Sfax en Tunisie. Bulletin de la Société de Pathologie Exotique, 111, 90-98.
https://bspe.revuesonline.com/article.jsp?langue=en&articleId=39461
https://doi.org/10.3166/bspe-2018-0024

[22]   Zahariadis, G., Gooley, T.A., Ryall, P., Hutchinson, C., Latchford, M.I., Fearon, M.A. and Jamieson, F.B. (2006) Risk of Ruling out Severe Acute Respiratory Syndrome by Ruling in Another Diagnosis: Variable Incidence of Atypical Bacteria Coinfection Based on Diagnostic Assays. Canadian Respiratory Journal, 13, 17-22.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539008
https://doi.org/10.1155/2006/862797


[23]   Borak, J. and Lefkowitz, R.Y. (2016) Bronchial Hyperresponsiveness. Occupational Medicine, 66, 95-105.
https://academic.oup.com/occmed/article/66/2/95/2750597
https://doi.org/10.1093/occmed/kqv158

[24]   Parrott, G.L., Kinjo, T. and Fujita, J. (2016) A Compendium for Mycoplasma pneumoniae. Frontiers in Microbiology, 7, Article No. 513.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828434/pdf/fmicb-07-00513.pdf
https://doi.org/10.3389/fmicb.2016.00513


[25]   Seggev, J.S., Sedmak, G.V. and Kurup, V. (1996) Isotype-Specific Antibody Responses to Acute Mycoplasma pneumoniae Infection. Annals of Allergy, Asthma and Immunology, 77, 67-73.
https://doi.org/10.1016/S1081-1206(10)63482-5
https://www.annallergy.org/article/S1081-1206(10)63482-5/pdf

[26]   Lim, K.G.E., Chong, V.C.L., Chan, S.S.W., Ong, K.H. and Kuperan, P. (2020) COVID-19 and Mycoplasma pneumoniae Coinfection. American Journal of Hematology, 95, 1.
https://doi.org/10.1002/ajh.25785

[27]   Gao, Z., Gao, L., Chen, X. and Xu, Y. (2020) A 49-Year-Old Women Co-Infected with SARS-CoV-2 and Mycoplasma—A Case Report. Infectious Diseases.
https://www.researchsquare.com/article/rs-16376/v1
https://doi.org/10.21203/rs.3.rs-16376/v1


[28]   Geng, Y.-J., Wei, Z.-Y., Qian, H.-Y., Huang, J., Lodato, R. and Castriotta, R.J. (2020) Pathophysiological Characteristics and Therapeutic Approaches for Pulmonary Injury and Cardiovascular Complications of Coronavirus Disease 2019. Cardiovascular Pathology. (In Press)
https://doi.org/10.1016/j.carpath.2020.107228

[29]   Bhatraju, P.K., Ghassemieh, B.J., Nichols, M., Kim, R., Jerome, K.R., Nalla, A.K., et al. (2020) Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. New England Journal of Medicine.
https://doi.org/10.1056/NEJMoa2004500
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143164

[30]   Papa, S. (1996) Mitochondrial Oxidative Phosphorylation Changes in the Life Span. Molecular Aspects and Physiopathological Implications. Biochimica et Biophysica Acta, 1276, 87-105.
https://doi.org/10.1016/0005-2728(96)00077-1
https://www.sciencedirect.com/science/article/pii/0005272896000771

[31]   Bohovych, I. and Khalimonchuk, O. (2016) Sending Out an SOS: Mitochondria as a Signaling Hub. Frontiers in Cell and Developmental Biology, 4, a109.
https://www.frontiersin.org/articles/10.3389/fcell.2016.00109/full
https://doi.org/10.3389/fcell.2016.00109


[32]   Murphy, M.P. and Hartley, R.C. (2018) Mitochondria as a Therapeutic Target for Common Pathologies. Nature Reviews in Drug Discovery, 17, 865-886.
https://www.nature.com/articles/nrd.2018.174
https://doi.org/10.1038/nrd.2018.174


[33]   Khan, M., Syed, G.H., Kim, S.-J. and Siddiqui, K. (2015) Mitochondrial Dynamics and Viral Infections: a Close Nexus. Biochimica et Biophysica Acta, 1853, 2822- 2833.
https://www.sciencedirect.com/science/article/pii/S0167488915000099
https://doi.org/10.1016/j.bbamcr.2014.12.040


[34]   Shi, C.S., Qi, H.Y., Boularan, C., Huang, N.N., Abu-Asab, M., Shelhamer, J.H. and Kehrl, J.H. (2014) SARS-Coronaviruses Open Reading Frame-9b Suppresses Innate Immunity by Targeting Mitochondria and the MAVS/TRAF3/TRAF6 Signalosome. Journal of Immunology, 193, 3080-3089.
https://doi.org/10.4049/jimmunol.1303196
https://www.jimmunol.org/content/jimmunol/193/6/3080.full.pdf

[35]   Sun, G., Xu, X., Wang, Y., Shen, X., Chen, Z. and Yang, J. (2008) Mycoplasma pneumoniae Infection Induces Reactive Oxygen Species and DNA Damage in A549 Human Lung Carcinoma Cells. Infection and Immunity, 76, 4405-4413.
https://iai.asm.org/content/iai/76/10/4405.full.pdf
https://doi.org/10.1128/IAI.00575-08

[36]   Xu, Z., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., et al. (2020) Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine, 8, 420-422.
https://www.thelancet.com/pdfs/journals/lanres/PIIS2213-2600(20)30076-X.pdf
https://doi.org/10.1016/S2213-2600(20)30076-X


[37]   Nicolson, G.L. and Ash, M.E. (2017) Membrane Lipid Replacement for Chronic Illnesses, Aging and Cancer Using Oral Glycerolphospholipid Formulations with Fructooligosaccharides to Restore Phospholipid Function in Cellular Membranes, Organelles, Cells and Tissues. Biochimica et Biophysica Acta Biomembranes, 1859, 1704-1724.
https://doi.org/10.1016/j.bbamem.2017.04.013

[38]   Nicolson, G.L., Settineri, R. and Ellithorpe, E. (2012) Glycophospholipid Formulation with NADH and CoQ10 Significantly Reduces Intractable Fatigue in Chronic Lyme Disease Patients: Preliminary Report. Functional Foods in Health and Disease, 2, 35-47.
http://www.functionalfoodscenter.net/files/50313126.pdf
https://doi.org/10.31989/ffhd.v2i3.100


[39]   Marchello, C., Dale, A.P., Thai, T.N., Han, D.S. and Ebell, M.H. (2016) Prevalence of Atypical Pathogens in Patients with Cough and Community-Acquired Pneumonia: A Meta Analysis. Annals of Family Medicine, 14, 552-566.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389400
https://doi.org/10.1370/afm.1993


[40]   Fernald, G.W. (1983) Immunologic Mechanisms Suggested in the Association of M. pneumoniae Infection and Extrapulmonary Disease: A Review. Yale Journal of Biology and Medicine, 56, 475-479.

[41]   Shimizu, T. (2016) Inflammation-Inducing Factors of Mycoplasma pneumoniae. Frontiers in Microbiology, 7, Article No. 414.
https://www.frontiersin.org/articles/10.3389/fmicb.2016.00414/full
https://doi.org/10.3389/fmicb.2016.00414


[42]   Simecka, J.W., Ross, S.E., Cassell, G.H. and Davis, J.K. (1993) Interactions of Mycoplasmas with B Cells: Antibody Production and Nonspecific Effects. Clinical Infectious Diseases, 17, S176-S182.
https://academic.oup.com/cid/article-abstract/17/Supplement_1/S176/309747?redirectedFrom=fulltext
https://doi.org/10.1093/clinids/17.Supplement_1.S176

[43]   Quentmeier, H., Schmitt, E., Kirchhoff, H., Grote, W. and Muhlradt, P.F. (1990) Mycoplasma fermentans-Derived High-Molecular-Weight Material Induces Interleukin-6 Release in Cultures of Murine Macrophages and Human Monocytes. Infection and Immunity, 58, 1273-1280.
https://iai.asm.org/content/58/5/1273
https://doi.org/10.1128/IAI.58.5.1273-1280.1990

[44]   Yi, Y., Lagniton, P.N.P., Ye, S., Li, E. and Xu, R.-H. (2020) COVID-19: What Has Been Learned and to Be Learned about the Novel Coronavirus Disease. International Journal of Biological Sciences, 16, 1753-1766.
https://www.ijbs.com/v16p1753.pdf
https://doi.org/10.7150/ijbs.45134


[45]   Lu, X., Pan, J., Tao, J. and Guo, D. (2011) SARS-CoV Nucleocapsid Protein Antagonizes IFN-beta Response by Targeting Initial Step of IFN-beta Induction Pathway, and Its C-Terminal Region Is Critical for the Antagonism. Virus Genes, 42, 37-45.
https://link.springer.com/article/10.1007/s11262-010-0544-x
https://doi.org/10.1007/s11262-010-0544-x

[46]   Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine.
https://doi.org/10.1056/NEJMoa2002032

[47]   Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qui, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet Respiratory Disease, 395, 507-513.
https://doi.org/10.1016/S0140-6736(20)30211-7

[48]   Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., et al. (2020) Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet, 395, 1054-1062.
https://www.thelancet.com/pdfs/journals/thelancet/PIIS0140-6736(20)30566-3.pdf
https://doi.org/10.1016/S0140-6736(20)30566-3


[49]   Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., et al. (2020) Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19. Thrombosis Research, 191.
https://www.thrombosisresearch.com/article/S0049-3848(20)30120-1/pdf
https://doi.org/10.1016/j.thromres.2020.04.013


[50]   Inamura, N., Miyashita, N., Hasegawa, S., Kato, A., Fukuda, Y., Saitoh, A., Kondo, E., et al. (2014) Management of Refractory Mycoplasma pneumoniae: Utility of Measuring Serum Lactate Dehydrogenase Level. Journal of Infection and Chemotherapy, 20, 270-273.
https://doi.org/10.1016/j.jiac.2014.01.001
https://www.sciencedirect.com/science/article/abs/pii/S1341321X14000737

[51]   Nesser, O.L., Vukajlovic, T., Felder, L., Haubitz, S., Hammerer-Lercher, A., Ottiger, C., Mueller, B., Schuetz, P. and Fux, C.A. (2019) A High C-Reactive Protein/Procalcitonin Ratio Predicts Mycoplasma pneumoniae Infection. Clinical Chemistry and Laboratory Medicine, 57, 1638-1646.
https://www.degruyter.com/view/journals/cclm/57/10/article-p1638.xml
https://www.ncbi.nlm.nih.gov/pubmed/31128571
https://doi.org/10.1515/cclm-2019-0194


[52]   Bar Meir, E., Amital, H., Levy, Y., Kneller, A., Bar-Dayan, Y. and Shoenfeld, Y. (2000) Mycoplasma-pneumoniae-Induced Thrombotic Thrombocytopenic Purpura. Acta Haematologica, 103, 112-115.
https://doi.org/10.1159/000041030
https://www.karger.com/Article/Abstract/41030

[53]   Rathinam, V.A.K. and Fitzgerald, K.A. (2011) Cytosolic Surveillance and Antiviral Immunity. Current Opinion in Virology, 1, 455-462.
https://www.sciencedirect.com/science/article/abs/pii/S1879625711001696
https://doi.org/10.1016/j.coviro.2011.11.004


[54]   Totura, A.L. and Baric, R.S. (2012) SARS Coronavirus Pathogenesis: Host Innate Immune Responses and Viral Antagonism of Interferon. Current Opinion in Virology, 2, 264-275.
https://doi.org/10.1016/j.coviro.2012.04.004
https://www.sciencedirect.com/science/article/pii/S1879625712000715-bib021054

[55]   Cameron, M.J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J.F., Cameron, C.M., Nuller, M.P., et al. (2007) Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome. Journal of Virology, 81, 8692-8706.
https://jvi.asm.org/content/81/16/8692
https://doi.org/10.1128/JVI.00527-07

[56]   Rottem, S. (2003) Interaction of Mycoplasmas with Host Cells. Physiological Reviews, 83, 417-432.
https://doi.org/10.1152/physrev.00030.2002

[57]   He, J., Liu, M., Ye, Z., Tan, T., Liu, X., You, X., Zeng, Y. and Wu, Y. (2016) Insights into the Pathogenesis of Mycoplasma penumoniae. Molecular Medicine Reports, 14, 4030-4036.
https://www.spandidos-publications.com/mmr/14/5/4030
https://doi.org/10.3892/mmr.2016.5765


[58]   Baseman, J.B. and Tully, J.G. (1997) Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety. Emerging Infectious Diseases, 3, 21-32.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627593/pdf/9126441.pdf
https://doi.org/10.3201/eid0301.970103


[59]   Minion, F.C., Jarvill-Taylor, K.J., Billings, D.E. and Tigges, E. (1993) Membrane-Associated Nuclease Activities in Mycoplasmas. Journal of Bacteriology, 175, 7842-7847.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC206960
https://doi.org/10.1128/JB.175.24.7842-7847.1993


[60]   Saitoh, S., Wada, T., Narita, M., Kohsaka, S., Mizukami, S., Togashi, T. and Kajii, N. (1993) Mycoplasma pneumoniae Infection May Cause Striatal Lesions Leading to Acute Neurologic Dysfunction. Neurology, 43, 2150-2151.
https://doi.org/10.1212/WNL.43.10.2150

[61]   Komada, Y., Zhang, X.L., Zhou, Y.W., Ido, M. and Azuma, E. (1997) Apoptotic Cell Death of Human Lymphoblastoid Cells Induced by Arginine Deaminase. International Journal of Hematology, 65, 129-141.
https://doi.org/10.1016/S0925-5710(96)00538-5

[62]   Nicolson, G.L. (2019) Pathogenic Mycoplasma Infections in Chronic Illnesses: General Considerations in Selecting Conventional and Integrative Treatments. International Journal of Clinical Medicine, 10, 477-522.
https://www.scirp.org/journal/paperinformation.aspx?paperid=95720
https://doi.org/10.4236/ijcm.2019.1010041


[63]   Rawadi, G., Roman-Roman, S., Castedo, M., Dutilleul, V., Susin, S., Marchetti, P., Geuskens, M. and Kroemer, G. (1996) Effects of Mycoplasma fermentans on the Myelomonocytic Linage. Different Molecular Endities with Cytokine-Inducing and Cytocidal Potential. Journal of Immunology, 156, 670-678.
https://www.jimmunol.org/content/156/2/670

[64]   Waites, K.B., Xiao, L., Liu, Y., Balish, M.F. and Atkinson, T.P. (2017) Mycoplasma pneumonia from the Respiratory Tract and Beyond. Clinical Microbiology Reviews, 30, 747-809.
https://doi.org/10.1128/CMR.00114-16

[65]   Becker, A., Kannan, T.R., Taylor, A.B., Pakhornova, O.N., Zhang, Y., Somarajan, S.R., Galaleldeen, A., Holloway, S.P., Baseman, J.B. and Hart, P.J. (2015) Structure of CARDS Toxin, a Unique ADP-Ribosylating and Vacuolating Cytotoxin from Mycoplasma pneumoniae. Proceedings of the National Academy of Sciences USA, 112, 5165-5170.
https://doi.org/10.1073/pnas.1420308112

[66]   Muir, M.T., Cohn, S.M., Louden, C., Kannan, T.R. and Baseman, J.B. (2011) Novel Toxin Assays Implicate Mycoplasma pneumoniae in Prolonged Ventilator Course and Hypoxemia. Chest, 139, 305-310.
https://doi.org/10.1378/chest.10-1222
https://journal.chestnet.org/article/S0012-3692(11)60069-X/pdf

[67]   Wang, Y., Lu, X., Chen, H., Chen, T., Su, N., Huang, F., Zhou, J., et al. (2020) Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. American Journal of Respiratory and Critical Care Medicine. (In Press)
https://doi.org/10.1164/rccm.202003-0736LE

[68]   Matute-Bello, G., Frevert, C.W. and Martin, T.R. (2008) Animal Models of Acute Lung Injury. American Journal of Physiology-Lung Cellular and Molecular Physiology, 295, L379-L399.
https://doi.org/10.1152/ajplung.00010.2008

[69]   Teijaro, J.R. (2017) Cytokine Storms in Infectious Diseases. Seminars in Immunopathology, 39, 501-517.
https://doi.org/10.1007/s00281-017-0640-2
https://link.springer.com/article/10.1007/s00281-017-0640-2

[70]   Tisoncik, J.R., Korth, M.J., Simmons, C.P., Farrar, J., Martin, T.R. and Katze, M.G. (2012) Into the Eye of the Cytokine Storm. Microbiology and Molecular Biology Reviews, 76, 16-32.
https://mmbr.asm.org/content/76/1/16
https://doi.org/10.1128/MMBR.05015-11

[71]   Nicholls, J., Dong, X.-P., Jang, G. and Peiris, M. (2003) SARS: Clinical Virology and Pathogenesis. Respirology, 8, S6-S8.
https://doi.org/10.1046/j.1440-1843.2003.00517.x

[72]   Yang, J., Hooper, W.C., Phillips, D.J. and Talkington, D.F. (2002) Regulation of Pro-Inflammatory Cytokines in Human Lung Epithelial Cells Infected with Mycoplasma pneumoniae. Infection and Immunity, 70, 3649-3655.
https://iai.asm.org/content/70/7/3649
https://doi.org/10.1128/IAI.70.7.3649-3655.2002

[73]   Nicolson, G.L., Nasralla, M.Y. and Nicolson, N.L. (1998) The Pathogenesis and Treatment of Mycoplasmal Infections. Antimicrobics and Infectious Diseases Newsletter, 17, 81-87.
https://doi.org/10.1016/S1069-417X(00)88885-8
https://www.sciencedirect.com/journal/antimicrobics-and-infectious-diseasesnewsletter/vol/17/issue/11

[74]   Sauter, P.M., van Rossum, A.M.C. and Vink, C. (2014) Mycoplasma pneumoniae in Children: Carriage, Pathogenesis and Antibiotic Resistance. Current Opinion in Infectious Diseases, 27, 220-227.
https://doi.org/10.1097/QCO.0000000000000063
https://journals.lww.com/co-infectiousdiseases/Abstract/2014/06000/Mycoplasma_pneumonia
e_in_children___carriage,.3.aspx

[75]   Kenny, G.E. and Cartwright, F.D. (2001) Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, Dalfopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalfopristin, and Telithromycin Compared to Their Susceptibilities to Reference Macrolides, Tetracyclines, and Quinolones. Antimicrobial Agents and Chemotherapy, 45, 2604-2608.
https://aac.asm.org/content/45/9/2604
https://doi.org/10.1128/AAC.45.9.2604-2608.2001

[76]   Arai, S., Gohara, Y., Kuwano, K. and Kawashima, T. (1992) Antimycoplasmal Activities of New Quinolones, Tetracyclines and Macrolides against Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy, 36, 1322-1324.
https://aac.asm.org/content/36/6/1322
https://doi.org/10.1128/AAC.36.6.1322

[77]   Renaudin, H. and Bébéar, C. (1990) Comparative in Vitro Activity of Azithromycin, Clarithromycin, Erythromycin and Lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. European Journal of Clinical Microbiology and Infectious Diseases, 9, 838-841.
https://link.springer.com/article/10.1007/BF01967388
https://doi.org/10.1007/BF01967388

[78]   Cao, B., Ren, L.-L., Zhao, R., Gonzalez, R., Song, S.-F., Bai, L., Yin, Y.D., et al. (2010) Viral and Mycoplasma pneumoniae Community-Acquired Pneumonia and Novel Clinical Outcome Evaluation in Ambulatory Adult Patients in China. European Journal of Clinical Microbiology and Infectious Disease, 29, 1443-1448.
https://link.springer.com/article/10.1007/s10096-010-1003-2
https://doi.org/10.1007/s10096-010-1003-2

[79]   Sch?gler, A., Kopf, B.S., Edwards, M.R., Johnston, S.L., Casaulta, C, Kleninger, E., Jung, A., Moeller, A., et al. (2015) Novel Antiviral Properties of Azithromycin in Cystic Fibrosis Airway Epithelial Cells. European Respiratory Journal, 45, 428-439.
https://erj.ersjournals.com/content/45/2/428
https://doi.org/10.1183/09031936.00102014

[80]   Retallack, H., Di Lullo, E., Arias, C., Knopp, K.A., Laurie, M.T. and Sandoval-Espinosa, C. (2016) Zika Virus Cell Tropism in the Developing Human Brain and Inhibition by Azithromycin. Proceedings of the National Academy of Sciences USA, 113, 14408-14413.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549
https://doi.org/10.1073/pnas.1618029113


[81]   Rubin, B.K. and Henke, M.O. (2004) Immunomodulatory Activity and Effectiveness of Macrolides in Chronic Airway Disease. Chest, 125, 70S-78S.
https://www.ncbi.nlm.nih.gov/pubmed/14872003
https://doi.org/10.1378/chest.125.2_suppl.70S


[82]   Min, J.-Y. and Jang, Y.J. (2012) Macrolide Therapy in Respiratory Viral Infections. Mediators of Inflammation, 2012, Article ID: 649570.
https://www.hindawi.com/journals/mi/2012/649570
https://doi.org/10.1155/2012/649570


[83]   Porter, J.D., Watson, J., Roberts, L.R., Gill, S.K., Groves, H., Dhariwal, J., Almond, M.H., et al. (2016) Indentification of Novel Macrolides with Antibacterial, Anti-Inflammatory and Type I and III INF-Augmenting Activity in Airway Epithelium. Journal of Antimicrobial Chemotherapy, 71, 2767-2781.
https://academic.oup.com/jac/article/71/10/2767/2388101
https://doi.org/10.1093/jac/dkw222

[84]   Lu, Z.K., Yuan, J., Li, M., Sutton, S.S., Rao, G.A., Jacob, S. and Bennett, C.L. (2015) Cardiac Risks Associated with Antibiotics: Azithromycin and Levofloxacin. Expert Opinion on Drug Safety, 129, 715-724.
https://www.tandfonline.com/doi/full/10.1517/14740338.2015.989210?scroll=top&needAccess=true
https://doi.org/10.1517/14740338.2015.989210


[85]   Gautret, P., Lagier, J.-C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., et al. (2020) Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 2020, Article ID: 105949.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549
https://doi.org/10.1016/j.ijantimicag.2020.105949


[86]   Chukwudi, C.U. (2016) rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines. Antimicrobial Agents and Chemotherapy, 60, 4433-4441.
https://aac.asm.org/content/aac/60/8/4433.full.pdf
https://doi.org/10.1128/AAC.00594-16

[87]   Vincent, M.J., Bergeron, E., Benjannet, S., Eirkson, B.R., Rollin, P.E., Ksiazek, T.G., Seidah, N.G. and Nichol, S.T. (2005) Chloroquine Is a Potent Inhibitor of SARS Coronavirus Infections and Spread. Virology Journal, 2, Article No. 69.
https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-2-69#citeas
https://doi.org/10.1186/1743-422X-2-69

[88]   Lim, H.-S., Im, J.-S., Cho, J.-Y., Bae, K.-S., Klein, T.A., Yeom, J.-S., Kim, T.-S., Choi, J.-C., Jang, I.-J. and Park, J.-W. (2009) Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 53, 1468-1475.
https://aac.asm.org/content/aac/53/4/1468.full.pdf
https://doi.org/10.1128/AAC.00339-08

[89]   Titus, E.O. (1989) Recent Developments in the Understanding of the Pharmacokinetics and Mechanism of Action of Chloroquine. Therapeutic Drug Monitoring, 11, 369-379.
https://doi.org/10.1097/00007691-198907000-00001
https://journals.lww.com/drug-monitoring/Abstract/1989/07000/Recent_Developments_in_the_
Understanding_of_the.1.aspx

[90]   Schroeder, M.E., Russo, S, Costa C., Hori, J., Tiscornia, I., Bollati-Fogolin, M., Zamboni, D.S., Ferreira, G., Cairoli, E. and Hill, M. (2017) Pro-Inflammatory Ca++-Activated K+ Channels Are Inhibited by Hydroxychoroquine. Nature Scientific Reports, 7, Article No. 1892.
https://doi.org/10.1038/s41598-017-01836-8
https://www.nature.com/articles/s41598-017-01836-8-citeas

[91]   Gao, J., Tian, Z. and Yang, X. (2020) Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies. Bioscience Trends, 14, 72-73.
https://doi.org/10.5582/bst.2020.01047
https://www.biosciencetrends.com/article/1883

[92]   Borba, M.G.S., Val, F.F.A., Sampaio, V.S., Alexandre, M.A.A., Melo, G.C., Brito, M., Mour?no, M.P.G., Brito-Sousa, J.D., et al. (2020) Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunct Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS2CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open, 3, e208857.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499
https://doi.org/10.1001/jamanetworkopen.2020.8857

[93]   Singh, A.K., Singh, A., Shaikh, A., Singh, R. and Misra, A. (2020) Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 with or without Diabetes: A Systemematic Search and a Narrative Review with a Special Reference to India and Other Developing Countries. Diabetes and Metabolic Syndrome: Clinical Research & Reviews, 14, 241-246.
https://doi.org/10.1016/j.dsx.2020.03.011
https://www.sciencedirect.com/science/article/pii/S1871402120300515

[94]   Li, H., Zhou, Y., Zhang, M., Wang, H., Zhao, Q. and Liu, J. (2020) Updated Approaches against SARS-CoV-2. Antimicrobial Agents and Chemotherapy. (In Press)
https://aac.asm.org/content/aac/early/2020/03/18/AAC.00483-20.full.pdf
https://doi.org/10.1128/AAC.00483-20

[95]   Nicolson, G.L., Ferreira de Mattos, G., Settineri, R., Costa, C., Ellithorpe, R., Rosenblatt, S., La Valle, J., Jimmenez, A. and Ohta, S. (2016) Clinical Effects of Hydrogen Administration: From Animal and Human Diseases to Exercise Medicine. International Journal of Clinical Medicine, 7, 32-76.
https://doi.org/10.4236/ijcm.2016.71005

[96]   Montagnier, L. and Blanchard, A. (1993) Mycoplasmas as Co-Factors in Infection Due to the Human Immunodeficiency Virus. Clinical Infectious Diseases, 17, S309- S315.
https://www.jstor.org/stable/4457254?seq=1

[97]   Blanchard, A. and Montagnier, L. (1994) AIDS Associated Mycoplasmas. Annual Review of Microbiology, 48, 687-712.
https://www.annualreviews.org/doi/pdf/10.1146/annurev.mi.48.100194.00335194
https://doi.org/10.1146/annurev.mi.48.100194.003351


[98]   Chakraborty, S. and Das, G. (2020) Secondary Infection by Anaerobic Bacteria Possibly Ensues a Battle for Oxygen in SARS-CoV-2 Infected Patients: Anaerobe-Targeting Antibiotics (Like Doxyclcine/Metronidazole) to Supplement Azithromycin in the Treatment of COVID19? OSF Preprints, April 10. (In Press)
https://doi.org/10.31219/osf.io/s48fv

[99]   Stricker, R.B. and Fesler, M.C. (2020) A Novel Plan to Deal with SARS-CoV-2 and COVID-19 Disease. Journal of Medical Virology, April 28. (In Press)
https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25945
https://doi.org/10.31219/osf.io/urzkd

 
 
Top